Display options
Cite
Sharib JM, Cyrus J, Horvai A, et al. Predictors of acute chemotherapy-associated toxicity in patients with Ewing sarcoma. Pediatr Blood Cancer. 2011;59(4):611-6doi: 10.1002/pbc.24031.
Sharib, J. M., Cyrus, J., Horvai, A., Gray Hazard, F. K., Neuhaus, J., Matthay, K. K., Goldsby, R., Marina, N., & DuBois, S. G. (2012). Predictors of acute chemotherapy-associated toxicity in patients with Ewing sarcoma. Pediatric blood & cancer, 59(4), 611-6. https://doi.org/10.1002/pbc.24031
Sharib, Jeremy M, et al. "Predictors of acute chemotherapy-associated toxicity in patients with Ewing sarcoma." Pediatric blood & cancer vol. 59,4 (2012): 611-6. doi: https://doi.org/10.1002/pbc.24031
Sharib JM, Cyrus J, Horvai A, Gray Hazard FK, Neuhaus J, Matthay KK, Goldsby R, Marina N, DuBois SG. Predictors of acute chemotherapy-associated toxicity in patients with Ewing sarcoma. Pediatr Blood Cancer. 2012 Oct;59(4):611-6. doi: 10.1002/pbc.24031. Epub 2011 Dec 16. PMID: 22180320; PMCID: PMC3310949.
Copy Download .nbib Format: NLM
Share it on

Pediatr Blood Cancer. 2012 Oct;59(4):611-6. doi: 10.1002/pbc.24031. Epub 2011 Dec 16.

Predictors of acute chemotherapy-associated toxicity in patients with Ewing sarcoma.

Pediatric blood & cancer

Jeremy M Sharib, Jobin Cyrus, Andrew Horvai, Florette K Gray Hazard, John Neuhaus, Katherine K Matthay, Robert Goldsby, Neyssa Marina, Steven G DuBois

Affiliations

  1. Department of Pediatrics, University of California, San Francisco School of Medicine, San Francisco, California 94143-0106, USA.

PMID: 22180320 PMCID: PMC3310949 DOI: 10.1002/pbc.24031

Abstract

BACKGROUND: Ewing sarcoma (ES) is a malignant tumor of bone and soft tissue of children and young adults. Patients with ES are treated with intensive chemotherapy regimens. We describe predictors of acute chemotherapy-associated toxicity in this population.

PROCEDURE: In this retrospective cohort study, records of ES patients treated at two academic medical centers between 1980 and 2010 were reviewed. Grade 3 and 4 non-hematologic chemotherapy-associated toxicities during frontline therapy were recorded for each patient, along with potential clinical and demographic predictors of toxicity. Bivariate analyses were performed using the Fisher exact test. Multivariate analysis was performed using logistic regression.

RESULTS: The cohort included 142 patients with ES and toxicity data. In bivariate analyses, age <12 years at diagnosis, Latino ethnicity, low family income, and treatment on a clinical trial were associated with higher incidence of toxicity (P < 0.01). Tumor size, site, stage, mode of local control, body mass index, overall chemotherapy exposure and dose-intensity were not associated with toxicity. In multivariate analysis, low income (odds ratio (OR) 4.97, 95% confidence interval (CI) 1.9-13.1), clinical trial enrollment (OR 3.67, 95% CI 1.2-10.9), pelvic tumor site (OR 3.88, 95% CI 1.17-12.88), and age <12 years (OR 2.8, 95% CI 1.0-7.5) were independent predictors of toxicity.

CONCLUSION: ES patients who are younger, of Latino ethnicity, have pelvic tumors or low income have higher rates of toxicity that may require increased supportive care. Treatment on a clinical trial was also associated with higher rates of toxicity, though this finding may reflect better reporting in these patients.

Copyright © 2011 Wiley Periodicals, Inc.

References

  1. J Clin Oncol. 2009 May 10;27(14):2405-14 - PubMed
  2. Clin Pediatr (Phila). 2009 Jul;48(6):601-8 - PubMed
  3. J Chemother. 2009 Dec;21(6):693-7 - PubMed
  4. J Pediatr Hematol Oncol. 2011 Mar;33(2):128-34 - PubMed
  5. J Toxicol Environ Health B Crit Rev. 2009;12(5-6):440-72 - PubMed
  6. Cancer. 2010 Jul 1;116(13):3189-94 - PubMed
  7. Health Aff (Millwood). 2007 Mar-Apr;26(2):331-44 - PubMed
  8. Br J Cancer. 2009 Apr 7;100(7):1026-31 - PubMed
  9. J Clin Oncol. 2006 Apr 1;24(10):1516-21 - PubMed
  10. Br J Haematol. 2004 May;125(4):421-34 - PubMed
  11. Lancet Oncol. 2010 Jan;11(1):75-84 - PubMed
  12. J Pediatr Hematol Oncol. 2009 Nov;31(11):803-11 - PubMed
  13. Hematology. 2008 Jun;13(3):142-6 - PubMed
  14. J Clin Oncol. 2010 Jul 10;28(20):3284-91 - PubMed
  15. Pediatr Blood Cancer. 2011 Jun;56(6):994-1002 - PubMed
  16. JAMA. 2005 Jan 12;293(2):203-11 - PubMed
  17. N Engl J Med. 2003 Feb 20;348(8):694-701 - PubMed
  18. Nat Genet. 2011 Mar;43(3):237-41 - PubMed
  19. J Natl Cancer Inst. 1991 Oct 16;83(20):1460-70 - PubMed
  20. Pediatr Blood Cancer. 2008 Apr;50(4):769-71 - PubMed
  21. Br J Haematol. 2009 Feb;144(3):388-94 - PubMed
  22. Pediatr Blood Cancer. 2007 Apr;48(4):447-52 - PubMed
  23. Neuro Oncol. 2009 Jun;11(3):292-300 - PubMed
  24. J Pediatr Hematol Oncol. 2008 Jun;30(6):425-30 - PubMed
  25. Lancet Oncol. 2010 Feb;11(2):184-92 - PubMed
  26. Scand J Public Health. 2006;34(5):544-54 - PubMed
  27. Pediatr Blood Cancer. 2006 Jul;47(1):22-9 - PubMed
  28. J Clin Oncol. 2009 Dec 10;27(35):5972-8 - PubMed
  29. Cancer. 2010 Feb 15;116(4):983-8 - PubMed
  30. Cancer. 2010 Apr 15;116(8):1964-73 - PubMed
  31. Ann Pharmacother. 2002 Sep;36(9):1344-50 - PubMed
  32. J Clin Oncol. 2009 May 20;27(15):2536-41 - PubMed
  33. Cancer Epidemiol Biomarkers Prev. 2011 Mar;20(3):449-53 - PubMed

MeSH terms

Publication Types

Grant support